Skip to main content
. 2020 Dec 12;11(12):1061. doi: 10.1038/s41419-020-03266-3

Fig. 1. Tazemetostat enhanced the sensitivity of 5-FU in CRC cells.

Fig. 1

A Western blotting of indicated proteins in the indicated cell lines. B mRNA level of indicated genes were analyzed by real-time PCR in the indicated cell lines. C Indicated cells were treated increasing dose of 5-FU for 24 h. Cell viability was analyzed by MTS. D Indicated cells were treated increasing dose of tazemetostat for 24 h. Cell viability was analyzed by MTS. E FHC cells were treated with 2.5 μg/mL 5-FU, 0.5 μM tazemetostat, or their combination for 24 h. Cell viability was analyzed by trypan blue. F CCD-18Co cells were treated with 2.5 μg/mL 5-FU, 0.5 μM tazemetostat, or their combination for 24 h. Cell viability was analyzed by trypan blue. G HCT116 cells were treated with 2.5 μg/mL 5-FU, 0.5 μM tazemetostat, or their combination for 24 h. Cell viability was analyzed by trypan blue. H DLD1 cells were treated with 2.5 μg/mL 5-FU, 0.5 μM tazemetostat, or their combination for 24 h. Cell viability was analyzed by trypan blue. I, J Sensitivity of HCT116 cells to 5-FU, tazemetostat, or their combination. Survival fraction (left) and the combination index (CI) (right) are shown. Fa, fraction affected. The results were expressed as the mean ± SD of three independent experiments. **P < 0.01.